The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

Approximately 70% of oropharyngeal cancer patients present at advanced stages \[[@REF1]\]. For these patients, two common treatment modalities exist: primary surgery with postoperative radiation (with or without chemotherapy) and primary chemoradiation (with or without salvage surgery). Both modalities achieve comparable survival outcomes for advanced stage oropharyngeal patients \[[@REF2]\], but there is still no consensus on a preferred treatment modality.

Modalities are selected based on anatomic location, patient factors/values, and physician influences. Despite similar tumour control rates, surgery causes significantly more complications that require remedial surgery, such as fistulas or permanent gastrostomies \[[@REF3]\]. Boscolo-Rizzo et al. \[[@REF4]\] found that chemoradiation had significantly higher long-term quality of life scores than surgery with postoperative radiation. A retrospective single centre study found that surgery followed by chemoradiation gave the patient population the best survival rates compared to surgery with postoperative radiotherapy or chemoradiotherapy alone \[[@REF5]\]; however, combining more treatment modalities often increases patient morbidity. Therefore, a trade off exists between tumour control and reduced side effects that physicians and patients must consider before selecting a treatment.

Before selecting a preferred modality, patients must consider the radiation dose to organs at risk (OAR) in the head and neck, such as the parotid glands, larynx, and mandible. While primary chemoradiation (CRT) prescribes a higher dose, adjuvant radiation (RT) may deliver more radiation to OAR because the entire post-surgical bed requires irradiation. Irradiating larger tissue volumes can increase the number and severity of side effects.

We hypothesize that the integral dose to the neck and dose to critical structures will be lower with primary CRT than adjuvant radiotherapy. Evaluating the difference in mean dose and maximum dose to OAR and the total integral dose between CRT and adjuvant RT will provide additional insight into the optimal treatment modality for locally advanced oropharyngeal cancer patients.

Materials and methods
=====================

The study was submitted for a Research Ethics Board (REB) review and follows the Tri-Council Policy Statement: Ethical Conduct for Research Involving Human Subjects (TCPS2), as data collection involved retrospective patient information such as computed tomography (CT) scans and radiotherapy treatment plans from the Cross Cancer Institute (Edmonton, Canada). The REB determined that ethics approval was not required as this is a quality improvement based study.

Using a retrospective cohort, we compared the total integral dose and dose to OAR that patients received when they were treated with adjuvant RT to a theoretical CRT plan using their preoperative CT scans. This study included both an experimental and control group as summarized in Figure [1](#FIG1){ref-type="fig"}.
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The last 20 consecutive patients with American Joint Committee on Cancer (AJCC) stage III or IVA oropharyngeal cancer who underwent primary surgery and postoperative radiotherapy for their disease at our centre between July 2015 and August 2016 were included in our study. Apart from the tumour resection surgery, patients had no previous head and neck surgeries for malignancies and no previous head and neck radiotherapy treatments.

We obtained the postoperative radiotherapy plans (60 Gy in 30 fractions delivered daily) and dose-volume-histograms (DVH) from the patients noted above to serve as our control group. Our standard procedure is to treat the post-surgical bed and involved lymph node levels to 60 Gy, and the uninvolved neck to 54 Gy. The radiation treatments were planned and completed at the Cross Cancer Institute. Each patient's plans and images were anonymized and assigned a random identification number.

For our experimental group, the patients' preoperative diagnostic CT scans were transferred to the ARIA® oncology information system for radiation oncology, which contains the radiotherapy treatment planning software used clinically at the Cross Cancer Institute. The parotid glands, submandibular glands, mandible, esophagus, larynx, and pharyngeal constrictor muscles were contoured as critical structures using the contouring guidelines from the Radiation Therapy Oncology Group (RTOG) protocol 1016. The RTOG 1016 protocol contains planning guidelines and objectives for target volumes and critical structures for primary chemoradiation of advanced stage oropharyngeal patients. A treatment couch structure was added to each plan to simulate the radiotherapy units. We generated volumetric arc therapy plans, which was the same technique used in postoperative plans, with the Eclipse 3D planning system (version 13.6, Varian Medical Systems, Palo Alto, CA). The dose prescription was different, 70 Gy in 33 fractions delivered daily, but the dose algorithm and plan normalization (95% of PTV received 100% of the dose) were maintained with the adjuvant RT plans to provide intrapatient consistency. Normal tissue optimizations were the same between postoperative and preoperative planning to reduce bias. Clinical target volume (CTV) to PTV margins were 0.5 cm in both groups. To account for the differences in fractionation, integral doses and OAR doses were converted to equivalent doses in 2 Gy fractions (EQD2).

As a form of quality assurance, a head and neck radiation oncologist and dosimetrist from the Cross Cancer Institute reviewed each contour and plan. The constructed primary CRT plan was compared to the patient's postoperative plan to assess the difference in integral dose and dose to OARs. Integral dose to the overall neck was calculated by multiplying the volume between the cochleas and the cricoid cartilage with the mean dose of that volume.

Data were analyzed using paired T-tests to determine any significant differences between the two regimes for each patient. A p-value of \< 0.05 was taken to be statistically significant. To determine our sample size, it was assumed that there would be a difference in integral dose between the two groups of 15% with a standard deviation of 10 for each group. Assuming a type I error of 0.05 and a type II error of 0.20, we required a total of 20 patients for statistical significance.

Results
=======

Data were collected for 20 patients, but two patients were omitted from analysis because of positional and scan size issues. Therefore, 18 patients were analyzed. Table [1](#TAB1){ref-type="table"} lists the patient characteristics of our sample group.

###### Patient Demographics, Pathology, and Surgery Results

  --------------------------------------------------- -----------------------------------------------------------------
  Demographic                                         Characteristics
  Age                                                 Median 64 (range 46-76)
  Sex                                                 94.7% male
  Subsite                                             50% base of tongue 27.8% tonsil 22.2% base of tongue and tonsil
  Clinical AJCC stage                                 5.3% III 94.7% IVA
  p16 status                                          83.3% positive 16.7% negative
  Extracapsular extension (ECE)                       66.7% positive 33.3% negative
  Lymphovascular invasion (LVI)                       38.9% positive 61.1% negative
  Perineural invasion (PNI)                           33.3% positive 66.7% negative
  Positive margins                                    22.2% positive 77.8% negative
  Percutaneous endoscopic gastrostomy tube inserted   44.4% after surgery (before RT) 11.1% during RT
  --------------------------------------------------- -----------------------------------------------------------------

The average high dose PTV volumes for the plans made on the patients' preoperative CT scans were 40.2% smaller compared to the postoperative plans, as seen in Table [2](#TAB2){ref-type="table"}.

###### Comparison of High Dose PTV Volumes and Integral Dose to the Head and Neck Region Between the Primary RT Cohort and Adjuvant RT Cohort

*Note: *All doses converted to 2 Gy fraction equivalent. P-value \</= 0.05 indicates statistical significance.

  ----------------------------------- ---------------------------- ---------------------------- -------------
                                      Primary RT                   Adjuvant RT                  P value
  High dose PTV volume (cc)           187.3 (95% CI 134.9-239.7)   466.3 (95% CI 356.7-575.9)   p \< 0.0001
  Integral dose to the neck (Gy\*L)   152.6 (95% CI 130.3-174.9)   156.6 (95% CI 134.7-178.5)   p=0.5375  
  ----------------------------------- ---------------------------- ---------------------------- -------------

The DVH comparison of the control group versus experimental plans revealed significant differences. Table [3](#TAB3){ref-type="table"} contains the mean and maximum dose averages for the critical structures analyzed between the two treatment groups. The maximum doses for the ipsilateral parotid gland, the mandible, the pharyngeal constrictor muscles, and the spinal cord were significantly lower for the adjuvant RT group. Also, the mean dose to the spinal cord was also significantly lower for the adjuvant RT group. On average, the primary CRT group had lower mean doses for the ipsilateral and contralateral parotid glands, esophagus, larynx, and mandible, but only doses to the ipsilateral and contralateral parotid glands and larynx were significantly lower than the adjuvant RT plans. The primary CRT group also had lower maximum doses for the contralateral parotid and oesophagus, but these differences were not statistically significant. The difference in the mean pharyngeal constrictor dose and max larynx dose was only 0.4 cGy and 1.1 cGy, respectively. Submandibular glands were resected for most patients so their dose comparisons were omitted. For individual patient doses, refer the Appendix.

###### Comparison of Mean and Maximum Doses to Critical Structures Between the Primary RT and Adjuvant RT Cohort

*Note: *All doses converted to 2 Gy per fraction equivalent. P-value \</= 0.05 indicates statistical significance.

  ----------------------------------------- --------------------------- ---------------------------- -------------
  Structure                                 Primary CRT (Gy)            Adjuvant RT (Gy)             P value
  Maximum dose to ipsilateral parotid       76.8 (95% CI 74.8-78.7)     65.7 (95% CI 64.4 to 67.0)   p \< 0.0001
  Mean dose to ipsilateral parotid          31.8 (95% CI 27.5-36.0)     39.3 (95% CI 35.4-43.1)      p = 0.0009
  Maximum dose to contralateral parotid     56.2 (95% CI 52.3-59.8)     58.4 (95% CI 52.6-64.1)      p = 0.4566
  Mean dose to contralateral parotid        22.5 (95% CI 22.1-22.8)     27.6 (95% CI 23.4-31.8)      p = 0.0238
  Maximum dose to esophagus                 46.4 (95% CI 42.3-50.6)     50.8 (95% CI 46.4-55.2)      p = 0.1266
  Mean dose to esophagus                    24.1 (95% CI 21.9 - 26.3)   29.7 (95% CI 23.3-36.1)      p = 0.0547
  Maximum dose to larynx                    59.5 (95% CI 53.2-65.8)     60.6 (95% CI 58.8-62.5)      p = 0.7307
  Mean dose to larynx                       20.7 (95% CI 19.3-22.2)     40.2 (95% CI 30.8-46.6)      p \< 0.0001
  Maximum dose to mandible                  75.7 (95% CI 72.9-78.6)     65.3 (95% CI 64.9-65.7)      p \< 0.0001
  Mean dose to mandible                     37.8 (95% CI 35.3-40.3)     40.6 (95% CI 38.0-43.2)      p = 0.1010
  Maximum dose to pharyngeal constrictors   77.4 (95% CI 76.4-78.3)     64.7 (95% CI 64.0 - 65.4)    p \< 0.0001
  Mean dose to pharyngeal constrictors      56.4 (95% CI 52.9-59.8)     56.8 (95% CI 55.0-58.7)      p = 0.7745
  Maximum dose to spinal cord               43.0 (95% CI 42.3-43.7)     40.9 (95% CI 40.1-41.6)      p \< 0.0001
  Mean dose to spinal cord                  31.6 (95% CI 30.4-32.9)     21.1 (95% CI 19.2-22.9)      p \< 0.0001
  ----------------------------------------- --------------------------- ---------------------------- -------------

Discussion
==========

Radiation therapy is commonly used to treat advanced stage oropharyngeal cancer, whether it be used adjuvant to surgery or as the primary modality along with chemotherapy \[[@REF2]\]. Beyond survival rates, there are very few studies that compare these two regimes. There is lack of randomized trials investigating quality of life following treatment with chemoradiation or surgery with postoperative radiation; therefore, a preferential treatment option still does not exist for these patients \[[@REF2]-[@REF4]\]. Though Tillman et al. \[[@REF6]\] studied a different tumour site with a different method, their results are consistent with ours in that their postoperative RT cohort had a larger PTV, and OARs such as the heart and lungs received a higher dose. Our study provides a similar dosimetric comparison and analysis that suggests that additional controlled studies are needed to further inform the patient's decision between these two treatment methods. As predicted, our study showed a significantly smaller mean high dose PTV for the primary CRT cohort, which was hypothesized to result in a lower integral dose. The primary CRT plans on average had lower integral doses. In fact, 14 out of 18 primary CRT plans had lower integral doses than their corresponding postoperative plans, although this was not significantly different, possibly due to the small number of patients in this study. Conversely, the results suggest that adjuvant RT is not advantageous over primary CRT in regards to delivering lower integral doses to a patient's normal tissues.

The mean ipsilateral and contralateral parotid gland dose was reduced by 19% and 18.5% in the primary CRT cohort, respectively. This reduction in dose to the parotids has major implications for the quality life of these patients, as the risk of xerostomia decreases. For every 1 Gy increase in parotid mean dose, salivary function decreases by 5% \[[@REF7]\]. If at least one parotid gland receives a mean dose of less than 25.8 Gy, the risk of grade 4 xerostomia is significantly lower. As the primary CRT contralateral parotid gland received less than 25.8 Gy and both adjuvant RT parotid glands received more than 25.8 Gy, we expect the primary CRT cohort to have a significantly lower risk of severe xerostomia, and, therefore, a better quality of life over the long-term.

While most submandibular RTOG 1016 dose targets were achieved for the primary CRT plans, many postoperative RT patients had their submandibular glands removed so dose statistics between the cohorts could not be compared. Though primary CRT delivers radiation to the submandibular glands, the risk of xerostomia due to submandibular irradiation is better than xerostomia from the absence of submandibular glands.

The primary CRT larynx structure had a 48.5% lower mean dose than adjuvant RT. Caudell et al. \[[@REF8]\] found that higher mean doses were significantly associated with severe dysphagia at 12 months post-treatment. Patients began to experience aspiration at a mean dose of 41 Gy to the larynx. At doses higher than the threshold, the risk of severe dysphagia is significantly correlated with increasing dosage. With the average mean dose of 40.2 Gy for adjuvant RT and 20.7 Gy for primary CRT, we would expect primary CRT patients to have a lower risk of aspiration. Also, as Caudell et al. \[[@REF8]\] only studied primary CRT, postoperative RT patients may experience more severe comorbidities at a mean dose of 41 Gy as patients irradiated postoperatively suffer lower quality of life and more severe pain with the same dose prescription comparison as our study \[[@REF4]\].

Our study's findings show that opting for surgery would not spare advanced oropharyngeal patients of the integral dose and that primary CRT lowers the mean dose to some OARs. Our results also indicated that treating a smaller volume to a higher dose in the primary CRT setting would not increase the risk of developing radiation-related side effects as there is a predicted lower risk of xerostomia and aspiration. In addition to potentially improving quality of life, lower toxicities can decrease appointment and treatment cancellations, which improves outcomes and decreases healthcare costs.

Due to a higher prescribed dose for the primary CRT cohort, we expected higher maximum doses received by many OARs than in the adjuvant RT cohort. The high dose PTV may overlap with some OARs, so maximum doses in those organs are difficult to avoid. The significantly higher maximum dose observed in the primary CRT cohort for the mandible would result in a higher risk of osteoradionecrosis. According to Emami \[[@REF9]\], this risk increases above 5% with a point dose greater than 70 Gy. Thankfully, most of the toxicity in head and neck critical structures are based on mean dose rather than point doses.

There were multiple limitations in our study. The primary CRT cohort was planned on diagnostic CT scans, and therefore the patients were not in a traditional RT position with an immobilizing shell with shoulders depressed and chin extended. This may have resulted in dosimetric differences between the cohorts, with a likely negative effect on the primary CRT group's OAR optimization abilities because these scans had compressed anatomy due to the lack of neck extension position in diagnostic scans. Secondly, although treating the post-surgical bed and bilateral neck for locally advanced oropharyngeal patients who have undergone surgery is standard at our center, it may not be so at other centers. There is evidence that postoperative radiotherapy to the ipsilateral neck may be all that's needed for patients with N2a-b disease \[[@REF10]\].

Conclusions
===========

In conclusion, primary CRT offered a lower total integral dose to the neck on average, although this was not statistically significant. Given that primary CRT plans prescribed a higher dose, higher maximum organ doses were expected. However, lower mean organ doses suggested that primary CRT plans spare more larynx and parotid gland than postoperative radiation, which may result in lower overall toxicity to the patient. Randomized clinical trials are necessary to further validate these findings and better inform the management decisions of advanced stage oropharyngeal cancer patients.
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Raw Data and Non-2 Gy Fraction Equivalent Doses for Each Patient and Critical Structure

###### Mean and Maximum Doses to Each Patient's Ipsilateral and Contralateral Parotids for Primary Radiotherapy (RT) and Postoperative Radiotherapy (PO).

  ----------- ------------------------------- ------------------------------- -------------------------------- --------------------------------- ----------- ----------- ----------- --------
  Patient     Max Ipsilateral Parotid  (Gy)   Mean Ipsilateral Parotid (Gy)   Max Contralateral Parotid (Gy)   Mean Contralateral Parotid (Gy)                                       
  [RT]{.ul}   [PO]{.ul}                       [RT]{.ul}                       [PO]{.ul}                        [RT]{.ul}                         [PO]{.ul}   [RT]{.ul}   [PO]{.ul}   
  1           75.978                          63.095                          38.563                           54.682                            54.718      57.448      25.341      37.933
  2           74.210                          64.622                          36.730                           38.668                            53.402      65.050      25.344      37.309
  3           75.845                          67.223                          36.689                           45.726                            53.977      64.805      25.258      39.933
  4           73.953                          62.092                          30.267                           37.896                            61.910      60.589      24.906      30.711
  6           76.897                          68.343                          25.758                           40.633                            70.347      64.245      25.124      37.533
  7           73.834                          59.448                          39.063                           37.998                            56.220      54.438      25.947      19.936
  8           75.258                          64.982                          51.725                           50.103                            54.314      60.896      25.272      26.159
  9           69.377                          64.032                          25.509                           34.649                            51.962      60.288      24.414      26.411
  10          75.626                          66.059                          40.951                           32.408                            54.544      55.916      25.277      24.255
  11          79.245                          65.102                          34.893                           36.877                            55.340      60.265      24.829      37.243
  12          71.596                          63.947                          29.201                           39.117                            55.832      58.189      25.430      30.013
  13          67.381                          64.863                          25.424                           42.677                            53.720      60.184      24.217      29.400
  14          75.950                          64.450                          23.626                           41.196                            76.040      64.450      23.286      41.196
  15          75.710                          64.135                          43.028                           38.344                            53.619      62.386      24.418      30.836
  17          81.209                          65.170                          48.659                           59.380                            56.979      62.166      25.123      19.327
  18          74.371                          63.987                          24.644                           39.116                            58.963      63.987      24.644      26.565
  19          75.496                          66.841                          35.684                           40.245                            55.770      16.705      26.419      7.918
  20          78.995                          68.918                          27.872                           33.896                            54.183      58.292      25.656      35.531
  ----------- ------------------------------- ------------------------------- -------------------------------- --------------------------------- ----------- ----------- ----------- --------

###### Mean and Maximum Doses to Each Patient's Mandible and Pharyngeal Constrictors (PC) for Primary Radiotherapy (RT) and Postoperative Radiotherapy (PO)

  ----------- ------------------- -------------------- ------------- -------------- ----------- ----------- ----------- --------
  Patient     Max Mandible (Gy)   Mean Mandible (Gy)   Max PC (Gy)   Mean PC (Gy)                                       
  [RT]{.ul}   [PO]{.ul}           [RT]{.ul}            [PO]{.ul}     [RT]{.ul}      [PO]{.ul}   [RT]{.ul}   [PO]{.ul}   
  1           68.856              65.511               31.564        44.637         75.970      64.975      55.198      60.188
  2           73.175              64.353               37.749        46.025         76.622      65.203      55.609      60.253
  3           75.541              64.873               38.780        39.858         74.602      65.756      55.975      60.891
  4           74.458              63.852               42.278        37.272         74.226      63.321      64.132      59.135
  6           77.206              63.510               46.251        46.686         76.499      64.414      66.692      61.856
  7           75.732              63.338               42.309        43.687         74.998      63.101      60.134      59.703
  8           75.758              65.564               44.287        35.177         76.066      64.929      60.220      61.241
  9           76.277              63.686               47.105        40.354         72.836      63.250      54.780      52.783
  10          75.696              65.306               39.936        47.274         75.666      64.125      54.709      53.728
  11          77.837              64.064               40.812        49.547         74.624      65.323      56.869      57.235
  12          63.747              63.776               33.739        42.059         75.202      64.009      56.302      59.157
  13          60.700              64.145               32.319        45.653         76.053      63.792      55.648      60.482
  14          76.805              63.892               45.635        47.381         74.715      64.14       60.078      61.575
  15          75.589              64.646               40.760        45.521         75.323      63.709      59.134      60.138
  17          79.150              65.395               44.039        46.895         76.996      63.544      56.490      55.535
  18          76.710              64.474               45.603        41.087         80.179      60.450      57.841      48.406
  19          76.005              65.394               37.279        31.915         73.515      64.288      55.708      37.185
  20          75.644              65.120               35.364        36.171         75.771      63.771      58.005      52.512
  ----------- ------------------- -------------------- ------------- -------------- ----------- ----------- ----------- --------

###### Mean and Maximum Doses to Each Patient's Larynx and Esophagus for Primary Radiotherapy (RT) and Postoperative Radiotherapy (PO)

  ----------- ----------------- ------------------ -------------------- --------------------- ----------- ----------- ----------- --------
  Patient     Max Larynx (Gy)   Mean Larynx (Gy)   Max Esophagus (Gy)   Mean Esophagus (Gy)                                       
  [RT]{.ul}   [PO]{.ul}         [RT]{.ul}          [PO]{.ul}            [RT]{.ul}             [PO]{.ul}   [RT]{.ul}   [PO]{.ul}   
  1           55.211            57.797             25.828               46.85                 48.947      58.157      29.360      45.744
  2           53.781            62.123             25.256               45.202                41.628      52.123      30.268      32.025
  3           53.460            60.269             25.091               24.870                58.375      34.771      22.414      16.311
  4           63.436            58.689             25.963               52.500                42.979      56.451      30.257      49.662
  6           68.064            64.414             25.584               61.856                59.767      62.881      29.832      51.394
  7           51.546            61.068             24.969               35.542                48.679      43.772      29.852      24.903
  8           77.158            56.392             24.675               30.797                57.147      51.000      17.937      13.933
  9           53.470            56.194             24.474               28.057                44.746      52.477      28.725      13.721
  10          49.455            60.581             24.688               34.448                47.729      50.196      29.819      25.512
  11          67.345            66.255             20.277               45.123                61.083      62.817      24.290      38.646
  12          62.682            63.936             20.934               58.526                50.893      59.882      25.541      28.115
  13          49.980            63.268             19.560               55.714                52.023      57.241      28.577      55.714
  14          55.298            63.130             18.920               58.253                44.076      58.117      26.263      34.192
  15          51.699            63.292             19.633               34.621                46.290      47.428      28.781      32.260
  17          73.034            60.214             27.990               31.747                49.850      46.782      29.616      29.198
  18          87.904            57.702             26.171               42.294                48.628      45.403      29.392      35.469
  19          57.484            55.129             18.715               25.358                40.465      37.482      26.139      21.093
  20          50.654            58.446             19.079               42.728                28.671      55.548      13.233      24.896
  ----------- ----------------- ------------------ -------------------- --------------------- ----------- ----------- ----------- --------

###### Mean and Maximum Doses to Each Patient's Spinal Cord, Integral Dose (ID), and PTV size for Primary Radiotherapy (RT) and Postoperative Radiotherapy (PO)

  ----------- --------------- ---------------- ----------- ----------- ----------- ----------- ----------- -------
  Patient     Max Cord (Gy)   Mean Cord (Gy)   ID (Gy/L)   PTV (cc)                                        
  [RT]{.ul}   [PO]{.ul}       [RT]{.ul}        [PO]{.ul}   [RT]{.ul}   [PO]{.ul}   [RT]{.ul}   [PO]{.ul}   
  1           46.862          43.608           37.008      27.592      96.20714    108.7386    61.7        442.3
  2           44.382          42.434           31.831      22.836      114.82917   133.9186    166.2       448.9
  3           44.891          43.280           34.376      20.895      115.65425   120.4623    174.7       390.5
  4           44.243          42.610           29.730      21.671      129.98775   135.6595    117.0       121.2
  6           46.612          42.823           37.577      26.060      143.41090   150.5132    315.5       981.7
  7           43.399          40.033           34.694      18.327      120.03611   92.2390     146.0       272.7
  8           46.314          44.487           29.391      27.487      129.75098   129.1895    267.9       496.2
  9           44.649          39.295           36.507      21.422      137.63596   135.1606    157         297.8
  10          43.798          43.371           33.189      21.675      97.36787    101.2248    139.4       443.8
  11          45.685          43.002           31.444      26.922      77.82079    85.48116    110.3       774.6
  12          46.341          42.588           34.935      26.45       117.54916   123.2601    171.2       378.3
  13          46.765          44.536           35.079      31.503      111.76074   127.5994    112.9       332
  14          43.081          42.441           34.711      21.151      177.38555   157.9239    484.2       836.3
  15          43.744          44.211           36.784      22.196      161.03830   174.4947    276.9       667.1
  17          47.43           42.632           35.924      22.762      137.34864   166.7237    302.2       462.8
  18          45.645          43.011           37.099      20.235      192.49248   170.0389    115.3       400.7
  19          47.234          44.071           35.906      15.803      111.88793   77.28451    72.1        212.8
  20          45.21           43.58            32.594      26.04       161.80963   140.346     181.6       433.6
  ----------- --------------- ---------------- ----------- ----------- ----------- ----------- ----------- -------
